Last edition
News about "VYKAT XR"
Neurocrine Biosciences to Acquire Soleno Therapeutics in USD 2.9 Billion Deal
The acquisition brings first-in-class Prader-Willi syndrome therapy VYKAT XR into Neurocrine’s portfolio, strengthening its position in endocrinology and rare diseases.
VYKAT XR | 07/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members